Zusammenfassung
Die vorliegende Leitliniensynopse umfasst die nationalen und internationalen Leitlinien, die bei der Erstellung der S3-Leitlinie »Demenzen« berücksichtigt wurden. Es werden die Kriterien für die Auswahl der Leitlinien, die systematische Bewertung der Leitlinien mit dem »Deutschen Instrument zur methodischen Leitlinien-Bewertung (DELBI)« und die von den Leitlinien angelegten Empfehlungsgraduierungen vorgestellt. Im Weiteren werden allen Empfehlungen der S3-Leitlinie »Demenzen«, für die eine Leitlinienrecherche durchgeführt wurde, die jeweiligen Empfehlungen mit Empfehlungsgraden und Literaturreferenzen aus den entsprechenden Leitlinien zugeordnet.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Referenzen
Chodosh J, Petitti D.B, Elliott M, et al.: Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc 2004; 52: 1051–1059. Level of evidence: F III
Cooper B, Bickel H, Schaufele, M: The ability of general practitioners to detect dementia and cognitive impairment in their elderly patients. A study in Mannheim. Int J Geriatr Psychiatry 1992; 7: 591–598. Level of evidence: III
Demers L, Oremus M, Perrault A, et al.: Review of outcome measurement instruments in Alzheimer’s disease drug trials: psychometric properties of functional and quality of life scales. J Geriatr Psychiatry Neurol 2000; 13: 170–180. Level of evidence: P IV
Holsinger T, Deveau J, Boustani M et al.: Does this patient have dementia? JAMA 2007, 297: 2391–2404. Level of evidence: D I a
Monnot M, Brosey M, Ross, E: Screening for dementia: family caregiver questionnaires reliably predict dementia. J Am Board Fam Pract 2005; 18: 240–256. Level of evidence: D III
O’Connor DW, Fertig A, Grande MJ, et al.: Dementia in general practice: the practical consequences of a more positive approach to diagnosis. Br J Gen Pract 1993; 43: 185–188. Level of evidence: III
Tekin S, Fairbanks LA, O’Connor S, et al.: Activities of daily living in Alzheimer’s disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 2001; 9: 81–86. Level of evidence: III
Referenzen
American Psychiatric Association (ed): Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: 1994: 142–143.
Holmes C, Cairns N, Lantos P, et al.: Validity of current clinical criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999; 174: 45–50.
Jobst KA, Barnetson LP, Shepstone BJ: Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and ApoE4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1998; 10: 271–302.
Jorm AF, Scott R, Cullen JS, et al.: Performance of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening test for dementia. Psychol Med 1991; 21: 785–790.
Lim A, Tsuang D, Kukull W, et al.: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999; 47: 564–569.
Lim HJ, Lim JP, Anthony P, et al.: Prevalence of cognitive impairment amongst Singapores elderly Chinese: a community-based study using the ECAQ and the IQCODE. Int J Geriatr Psychiatry 2003; 18: 142–148.
Kua EH, Ko SM: A questionnaire to screen for cognitive impairment among elderly people in developing countries. Acta Psychiatr Scand 1992; 85: 119–122.
Kua EH, Ko SM. Prevalence of dementia among elderly Chinese and Malay residents of Singapore. Int Psychogeriatr 1995; 7: 439–446.
Sahadevan S, Lim PP, Tan NJ, et al.: Diagnostic performance of two mental status tests in the older Chinese: influence of education and age on cut-off values. Int J Geriatr Psychiatry 2000; 15: 234–241.
Referenzen
Brodaty H, Pond D, Kemp NM, et al.: The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 2002; 50: 530–534.
Darvesh S, Leach L, Black SE, et al.: The behavioural neurology assessment. Can J Neurol Sci 2005; 32: 167–177.
Kalbe E, Kessler J, Calabrese P, et al.: DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19: 136–143.
Nasreddine ZS, Phillips NA, Bedirian V: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
Solomon PR, Hirschoft A, Kelly B, et al.: A 7 minute neurocognitive screening battery highly sensitive to Alzheimer’s disease. Arch Neurol 1998; 55: 349–355.
Referenzen
Boustani M, Peterson B, Hanson L, et al.: Screening for dementia in primary care: a summary of the evidence for the U.S. preventive services task force. Ann Int Med. 2003; 138: 927–937.
Referenzen
Golding E: MEAMS: The Middlesex Elderly Assessment of Mental State. Thames Valley Test Company, Titchfield 1989.
Hentschel F, Kreis M, Damian M, et al.: The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study. Int J Geriatr Psychiatry 2005; 20: 645–650.
Mathuranath PS, Nestor PJ, Berrios GE, et al.: A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 2000; 55: 1613–1620.
Randolph C: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Harcourt Assessment, London 1998.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–1364.
Roth M, Huppert FA, Mountjoy CQ, et al.: CAMDEX-R: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge University Press, Cambridge 1998.
Williams JG, Huppert FA, Matthews FE, et al.: Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. Int J Geriatr Psychiatry 2003; 18: 631–644.
Brinkmeyer J, Grass-Kapanke B, Ihl R: EEG and the Test for the Early Detection of Dementia with Discrimination from Depression (TE4D): a validation study. Int J Geriatr Psychiatry 2004; 19: 749–753. Level of evidence: D III
Fischer-Altevogt L, Calabrese P, Kalbe E, et al.: DemTect: A new diagnostic tool in the detection of dementia. Revue Geriatr 2002; 27: 437–444. Level of evidence: D III
Grass-Kapanke B, Brieber S, Pentzek M, et al.: Der TFDD — Test zur Früherkennung von Demenzen mit Depressionsabgrenzung. Z Gerontopsychol Psychiatr 2005; 18: 155–167. Level of evidence: D III
Ihl R, Grass-Kapanke B, Lahrem P, et al.: Entwicklung und Validierung eines Tests zur Früherkennung der Demenz mit Depressionsabgrenzung (TFDD). Fortschr Neurol Psychiatr 2000; 68: 413–422. Level of evidence: D III
Kalbe E, Kessler J, Calabrese P et al.: DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19: 136–143. Level of evidence: D III
Kalbe E, Brand M, Kessler, RK et al.: Der DemTect in der klinischen Anwendung. Sensitivität und Spezifität eines kognitiven Screeninginstruments. Z Gerontopsychol Psychiatr 2005; 18: 121–130. Level of evidence: D III
Kessler J, Calabrese P, Kalbe E, et al.: DemTect: A new screening method to support diagnosis of dementia. Psycho 2000; 26: 343–347. Level of evidence: D III
Mahoney R, Johnston K, Katona C, et al.: The TE4D-Cog: a new test for detecting early dementia in English-speaking populations. Int J Geriatr Psychiatry 2005; 20: 1172–1179. Level of evidence: D III
Perneczky R: The appropriateness of short cognitive tests for the identification of mild cognitive impairment and mild dementia. Akt Neurol 2003; 30: 114–117. Level of evidence: D III
Scheurich A., Muller MJ, Siessmeier T, et al.: Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early Alzheimer disease in patients of a memory clinic. Dement Geriatr Cogn Disord 2005; 20: 271–277. Level of evidence: D III Referenzen
Von Aster M, Neubauer A, Horn R (Hrsg): Wechsler Intelligenztest für Erwachsene (WIE). Deutschsprachige Bearbeitung und Adaptation des WAIS-III von David Wechsler. Harcourt Test Services, Frankfurt/Main 2006.
Bucks RS, Ashworth DL, Wilcock GK, et al.: Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996; 25: 113–120.
Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989; 19: 1015–1022.
Bund deutscher Allgemeinärzte (BDA): Manual Demenz. BDA, Emsdetten 1999. Level of evidence: keine Angabe
Reisberg B, Finkel S, Overall J, et al.: The Alzheimer’s disease activities of daily living international scale (ADL-IS). Int Psychogeriatr 2001; 13: 163–181. Level of evidence: III
Zeitler HP, Gulich M: Leitlinie Ältere Sturzpatienten. DEGAM-Leitlinie 4, Hrsg.: DGfA.u. Familienmedizin. DEGAM und omikron publishing, Düsseldorf 2004. Level of evidence: keine Angabe
Alexopoulos GS, Abrams RC, Young RC, et al.: Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271–284.
American Psychiatric Association (ed): Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC, 1987.
Chong MS, Sahadevan S: An evidence-based clinical approach to the diagnosis of dementia. Ann Acad Med Singapore 2003; 32: 40–48.
Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–2314.
Lam CK, Lim PP, Low BL, et al.: Depression in dementia: a comparative and validation study of four brief scales in the elderly Chinese. Int J Geriatr Psychiatry 2004; 19: 422–428.
Lim PP, Ng LL, Chiam PC, et al.: Validation and comparison of three brief depression scales in an elderly Chinese population. Int J Geriatr Psychiatry 2000; 15: 824–830.
Lim WS, Chin JJ, Lam CK, et al.: Clinical dementia rating: experience of a multi-racial Asian population. Alzheimer Dis Assoc Disord 2005; 19: 135–142.
Morris J C: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–2414.
Reisberg B, Borenstein J, Salob SP, et al.: Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48: 9–15.
Referenzen
Boustani M, Peterson B, Harris R, et al.: Screening for Dementia. Systematic Evidence Review No. 20. Agency for Healthcare Research and Quality. Rockville, MD, June 2003.
Costa PT Jr, Williams T, Somerfield M, et al.: Early identification of Alzheimer’s disease and related dementias. Clinical Practice Guideline, Quick Reference Guide for Clinicians, No. 19. Vol. AHCPR Publication No. 97-0703. Rockville, MD 1996: 1–28.
Law S, Wolfson C: Validation of a French version of an informant-based questionnaire as a screening test for Alzheimer’s disease. Br J Psychiatry 1995; 167: 541–544.
Referenzen
Clarfield AM: The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 2003; 163: 2219–2229.
Burke D, Sengoz A, Schwartz R: Potentially reversible cognitive impairment in patients presenting to a memory disorders clinic. J Clin Neurosci 2000; 7: 120–123.
Massoud F, Devi G, Moroney JT, et al.: The role of routine laboratory studies and neuroimaging in the diagnosis of dementia: A clinicopathological study. J Am Geriatr Soc 2000; 48: 1204–1210.
Referenzen
Kasa M, Bierma TJ, Waterstraat F, Jr, et al.: Routine blood chemistry screen: a diagnostic aid for Alzheimer’s disease. Neuroepidemiology 1989; 8: 254–261. Level of evidence: III
Larson EB, Reifler BV, Sumi S, et al.: Diagnostic tests in the evaluation of dementia. A prospective study of 200 elderly outpatients. Arch Intern Med 1986; 146: 1917–1922. Level of evidence: IV
Referenzen
Practice parameter for diagnosis and evaluation of dementia (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994; 44: 2203–2206.
Referenzen
Knopman DS, de Kosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology 2001; 56: 1143–1153.
Referenzen
Garcia A, Zanibbi K: Homocysteine and cognitive function in elderly people. CMAJ 2004; 171: 897–904.
Malouf R, Areosa Sastre A: Vitamin B12 for cognition. Cochrane Database Syst Rev. 2003 (3): CD004326.
Wright CB, Lee HS, Paik MC, et al.: Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. Neurology 2004; 63: 254–260.
Referenzen
Clarfield AM: The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 2003; 163: 2219–2229.
Knopman DS, de Kosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–1153.
Petersen RC, Stevens JC, Ganguli M, et al.: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology 2001; 56: 1133–1142.
Referenzen
Kuusisto J, Koivisto K, Kervinen K, et al.: Association of apolipoprotein E phenotypes with late onset Alzheimer’s disease: population based study. Br Med J 1994; 309: 636–638.
Pedersen NL, Gatz M, Berg S, et al.: How heritable is Alzheimer’s disease late in life? Findings from Swedish twins. Ann Neurol 2004; 55: 180–185.
Skoog I, Hesse C, Aevarsson O, et al.: A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease and mortality. J Neurol Neurosurg Psychiatry 1998; 64: 37–43.
Referenzen
Arzneimittelkommission der deutschen Ärzteschaft (AKDÄ), Höffler D, Lasek, R et al. (Hrsg): Demenz. Arzneiverordnung in der Praxis (AVP). Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft. 3. Aufl. AKDÄ, Köln 2004.
Referenzen
American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease, Farrer LA, Brin MF et al.: Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995; 274: 1627–1629. (G)
Knopman DS, De Kosky ST, Cummings JL, et al.: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–1153. (G)
Mayeux R, Saunders AM, Shea S, et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med 1998; 338: 506–511. (G)
National Institute on Aging/Alzheimer’s Association Working Group, Relkin NR: Apolipoprotein E genotyping in Alzheimer’s disease. Lancet 1996; 347: 1091–1095. (G)
Referenzen
American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease, Farrer LA, Brin MF et al.: Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995; 274: 1627–1629.
American Geriatrics Society Ethics Committee: Genetic testing for late-onset Alzheimer’s disease. J Am Geriatr Soc 2001; 49: 225–226.
Connell LM, Koenig BA, Greely HT, et al.: Genetic testing and Alzheimer disease: Has the time come? Nat Med 1998; 4: 757–759.
Mayeux R, Saunders AM, Shea S, et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med 1998; 338: 506–511.
Post SG: Key issues in the ethics of dementia care. Neurol Clin 2000; 18: 1011–1022.
Post SG, Whitehouse PJ, Binstock RH, et al.: The clinical introduction of genetic testing for Alzheimer’s disease. JAMA 1997; 277: 832–836.
Referenzen
Knopman DS, de Kosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology 2001; 56: 1143–1153.
Referenzen
Chui H, Zhang Q: Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology’s practice parameters. Neurology 1997; 49: 925–935.
Clarfield AM: The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Int Med 2003; 163: 2219–2229.
Gifford DR, Holloway RG, Vickrey BG: Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. Arch Int Med 2000; 160: 2855–2862.
Royal College of Psychiatrists: Forgetful but not forgotten: assessment and aspects of treatment of people with dementia by a Specialist Old Age Psychiatry Service. Royal College of Psychiatrists, London 2005.
Referenzen
Chui H, Zhang Q: Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology’s practice parameters. Neurology 1997; 49: 925–935. Level of evidence: III
Condefer KA, Haworth J, Wilcock GK: Clinical utility of computed tomography in the assessment of dementia: a memory clinic study. Int J Geriatr Psychiatry 2004; 19: 414–421. Level of evidence: keine Angaben
Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia: Assessing dementia: the Canadian consensus. CMAJ 1991; 144: 851–853. Level of evidence: keine Angaben
Referenzen
Chui H, Zhang Q: Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurologys practice parameters. Neurology 1997; 49: 925–935.(G)
Referenzen
Patterson CJ, Gauthier S, Bergman H, et al.: The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ 1999; 160: S1–15.
Sitoh YY, Kanagasabai K, Sitoh YY, et al.: Evaluation of dementia: The case for neuroimaging all mild to moderate cases. Ann Acad Med Singapore 2006; 35: 383–389.
Referenzen
Patterson C, Gauthier S, Bergman H, et al.: The recognition, assessment and management of dementing disorders: Conclusions from the Canadian consensus conference on dementia Can J of Neurol Sci 2001; 28 (Suppl 1): S3–S16.
Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia, Montreal, March 9–11, 2006.
Referenzen
Barber R, Gholkar A, Scheltens P, et al.: Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999; 52: 1153–1158.
Roman GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international Workshop. Neurology 1993; 43: 250–260.
Referenzen
Knopman DS, de Kosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology 2001; 56: 1143–1153.
Referenzen
van Straaten EC, Scheltens P, Knol DL, et al.: Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003; 34: 1907–1912.
Referenzen
Jagust W, Thisted R, Devous MD Sr, et al.: SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: a clinicalpathologic study. Neurology 2001; 56: 950–956.
Mielke R, Heiss WD: Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia. J Neural Transm Suppl 1998; 53: 237–250.
Mosconi L: Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32: 486–510.
Patwardhan MB, McCrory DC, Matchar DB, et al.: Alzheimer’s disease: operating characteristics of PET — a meta-analysis. Radiology 2004; 231: 73–80.
Referenzen
Donnemiller E, Heilmann J, Wenning GK, et al.: Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24: 320–325.
Dougall N, Bruggink S, Ebmeier KP: The clinical use of 99mTc-HMPAO SPECT in Alzheimer’s Disease. Adv Biol Psychiatry 2003; 22: 4–37.
Dougall N, Nobili F, Ebmeier KP: Predicting the accuracy of a diagnosis of Alzheimer’s disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Res 2004 a; 131: 175–168.
Dougall NJ, Bruggink S, Ebmeier KP: Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004 b; 12: 554–570.
Fleming JS, Kemp PM, Bolt L, et al.: Measurement of cerebral perfusion volume and 99mTc-HMPAO uptake using SPECT in controls and patients with Alzheimer’s disease. Nucl Med Commun 2002; 23: 1057–1064.
Jagust W, Thisted R, Devous MD, Sr., et al.: SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: A clinicalpathologic study. Neurology 2001; 56: 950–956.
Sjogren M, Gustafson L, Wikkelso C, et al.: Frontotemporal dementia can be distinguished from Alzheimer’s disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio. Dement Geriatr Cogn Disord 2000; 11: 275–285.
Talbot PR, Lloyd JJ, Snowden JS, et al.: A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 1998; 64: 306–313.
Referenzen
Gill SS, Rochon PA, Guttman M, et al.: The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc. 2003; 51: 258–264.
Referenzen
Knopman DS, de Kosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–1153.
Referenzen
Sunderland T, Linker G, Mirza N, et al.: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094–2103.
Referenzen
Rosen I: Electroencephalography as a diagnostic tool in dementia. Dement Geriatr Cogn Disord 1997; 8: 110–116.
Referenzen
Lippa CF, Swearer JM, Kane KJ, et al.: Familial Alzheimer’s disease: site of mutation influences clinical phenotype. Ann Neurol 2000; 48: 376–379.
Morris JC: Dementia update 2005. Alzheimer Dis Assoc Disord 2005; 19: 100–117.
Referenzen
Baker M, Mackenzie IR, Pickering-Brown SM, et al.: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916–919. (G)
Blacker D: New insights into genetic aspects of Alzheimer’s disease: does genetic information make a difference in clinical practice? Postgrad Med 2000; 108: 119–122, 125–126, 129. (G)
Goate A, Chartier-Harlin MC, Mullan M, et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991; 349:704–706. (G)
Goldman JS, Farmer JM, van Deerlin VM, et al.: Frontotemporal dementia: genetics and genetic counseling dilemmas. Neurologist 2004; 10: 227–234. (G)
Inouye SK, Bogardus ST Jr, Charpentier PA, et al.: A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999; 340: 669–676. (G)
Levy-Lahad E, Wasco W, Poorkaj P, et al.: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995; 269: 973–977. (G)
Post SG, Whitehouse PJ, Binstock RH, et al.: The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997; 277: 832–836. (G)
Sherrington R, Rogaev EI, Liang Y, et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995; 375: 754–760. (G)
Referenzen
Knopman DS, de Kosky ST, Cummings JL, et al.: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–1153.
Referenzen
Nussbaum RL, Ellis CE: Genomic Medicine: Alzheirmers disease and Parkinsons disease. N Engl J Med 2003; 348: 1356–1364.
Referenzen
Birks J, Grimley Evans J, Iakovidou V, et al.: Rivastigmine for Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.
Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
Blesa R, Davidson M, Kurz A, et al.: Galantamine provides sustained benefits in patients with ‘advanced moderate’ Alzheimer’s disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15: 79–87.
Bullock R, Erkinjuntti T, Lilienfeld S, Group G-I-S: Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004; 17: 29–34.
Clegg A, Bryant J, Nicholson T, et al.: Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: A systematic review. Int J Technol Assess Health Care 2002; 18: 497–507.
Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatric Psychopharmacol 1998; 1: 55–65.
Doraiswamy PM, Krishnan KRR, Anand R, et al.: Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: Does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 705–712.
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial [comment]. Lancet 2002; 359: 1283–1290.
Feldman H, Gauthier S, Hecker J, et al.: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737–744.
Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–595.
Rosler M, Anand R, Cicin-Sain A, et al.: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial [comment][erratum appears in BMJ 2001;322 (7300):1456]. BMJ 1999; 318: 633–638.
Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD: The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–2276.
Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–1599.
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: Multicentre randomised controlled trial. BMJ 2000; 321: 1445–1449.
Wilkinson D, Murray J: Galantamine Research G. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 852–857.
Wolfson C, Oremus M, Shukla V, et al.: Donepezil and rivastigmine in the treatment of Alzheimer’s disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002; 24: 862–886.
Referenzen
Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer’s disease. Cochrane Database Syst Rev 2003; (2). Level of evidence: Ia
Burns A, Rossor M, Hecker J, et al.: The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord, 1999; 10: 237–244. Level of evidence: Ib
Courtney C, Farrell D, Gray R, et al.: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–2115. Level of evidence: keine Angabe
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620. Level of evidence: TIb
Frankfort SV, Appels BA, de Boer A, et al.: Identification of responders and reactive domains to rivastigmine in Alzheimer’s disease. Pharmacoepidemiol Drug Saf 2007; 16: 545–551. Level of evidence: TIII
Greenberg SM, Tennis MK, Brown LB, et al.: Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–99. Level of evidence: keine Angabe
Holmes C, Burns A, Passmore P, et al.: AD 2000: design and conclusions. Lancet 2004 a; 364: 1213–1214; author reply 1216–1217. Level of evidence: keine Angabe
Holmes C, Wilkinson D, Dean C, et al.: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004 b; 63: 214–219. Level of evidence: keine Angabe
Homma A, Takeda M, Imai Y, et al.: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299–313. Level of evidence: Ib
Kaduszkiewicz H, Beck-Bornholdt HP, van den Bussche H, et al.: Fragliche Evidenz für den Einsatz des Cholinesterasehemmer Donepezil bei Alzheimer-Demenz — eine systematische Übersichtsarbeit. Fortschr Neurol Psychiatr 2004; 72: 557–563. Level of evidence: keine Angabe
Kaiser T, Florack C, Franz H, Sawicki PT: Donepezil bei Patienten mit Alzheimer-Demenz. Die AD2000-Studie. Med Klinik 2005; 100: 157–160. Level of evidence: keine Angabe
Lanctot KL, Herrmann N, Yau KK, et al.: Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a metaanalysis. CMAJ 2003; 169: 557–564. Level of evidence: keine Angabe
Mohs RC, Doody RS, Morris JC, et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–488. Level of evidence: Ib
N.N.: Alzheimer-Mittel Donepezil (Aricept) ohne relevanten Nutzen. Arznei-Telegramm 2004; 35: 67–68. Level of evidence: keine Angabe
Olin J, Schneider L: Galantamine for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev 2003; (2). Level of evidence: Ia
Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293–303. Level of evidence: Ib
Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67–75. Level of evidence: Ib
Rogers SL, Doody RS, Mohs R, et al.: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 a; 158: 1021–1031. Level of evidence: Ib
Rogers SL, Farlow MR, Doody RS, et al.: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 b; 50: 136–145. Level of evidence: Ib
Schneider LS: AD 2000: donepezil in Alzheimer’s disease. Lancet 2004; 363: 2100–2101. Level of evidence: keine Angabe
Stoppe G, Pirk O, Haupt M: Therapie der Alzheimer-Demenz mit der besten verfügbaren Evidenz — eine Utopie? Gesundheitswesen 2005; 67: 20–26. Level of evidence: IV
Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–1599. Level of evidence: Ib
Trinh NH, Hoblyn J, Mohanty S, et al.: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003, 289: 210–216. Level of evidence: Ia
Whitehead A, Perdomo C, Pratt RD, et al.: Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a metaanalysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19: 624–633. Level of evidence: Ia
Williams PS, Rands G, Orrel M, et al.: Aspirin for vascular dementia (Cochrane Review). Cochrane Database Syst Rev 2003; (2). Level of evidence: Ia
Wimo A, Winblad B, Engedal K, et al.: An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15: 44–54. Level of evidence: Ib
Winblad B, Engedal K, Soininen H, et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–495. Level of evidence: keine Angabe
Referenzen
Agid Y, Dubois B, Anand R, et al.: Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp 1998; 59: 837–845. (A)
Brodaty H, Corey-Bloom J, Potocnik FC, et al.: Galantamine prolonged release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20: 120–132. (A)
Burns A, Rossor M, Hecker J, et al.: The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–244. (A)
Corey-Bloom J, Anand R, Veach J, ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65. (A)
Courtney C, Farrell D, Gray R, et al.: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–2115. (A)
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620. (A)
Forette F, Anand R, Gharabawi G: A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 1999; 6: 423–429. (A)
Greenberg SM, Tennis MK, Brown LB, et al.: Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–99. (A)
Karaman Y, Erdogan F, Koseoglu E, et al.: A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 19: 51–56. (A-)
Lopez OL, Becker JT, Saxton J, et al.: Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J Am Geriatr Soc 2005; 53: 83–87. (C)
Mohs RC, Doody RS, Morris JC, et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–488. (A)
Raskind MA, Peskind ER, Wessel T, et al.: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–2268. (A)
Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–595. (A)
Rogers SL, Farlow MR, Doody RS, et al.: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 a; 50: 136–145. (A)
Rogers SL, Doody RS, Mohs RC, et al.: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 b; 158: 1021–1031. (A)
Rosler M, Anand R, Cicin-Sain A, et al.: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–638. (A)
Seltzer B, Zolnouni P, Nunez M, et al.: Efficacy of donepezil in early stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852–1856. (A)
Sramek JJ, Anand R, Wardle TS, et al.: Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer’s disease. Life Sci 1996; 58:1201–1207. (A)
Suh GH, Yeon JH, Uk LC, et al.: A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population. Clin Ther 2004; 26: 1608–1618. (A)
Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebocontrolled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–2276. (A)
Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–1599. (A)
Tune L, Tiseo PJ, Ieni J, et al.: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003; 11: 169–177. (A)
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445–1449. (A)
Wilkinson D, Murray J: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 852–857. (A)
Winblad B, Engedal K, Soininen H, et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–495. (A)
Winblad B, Kilander L, Eriksson S, et al.: Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057–1065. (A)
Referenzen
Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer’s disease. In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Birks J, Grimley Evans J, Iakovidou V, et al.: Rivastigmine for Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2005. Oxford: Update Software.
Courtney C, Farrell D, Gray R, et al.: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD 2000): randomized double-blind trial. Lancet 2004; 363: 2105–2115.
Loy C, Schneider L: Galantamine for Alzheimer’s disease and mild cognitive impairment. In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Raskind MA, Peskind ER, Truyen L, et al.: The cognitive benefits of galantamine are sustained for at least 36 months; a long-term extension trial. Arch Neurol 2004; 61: 252–256.
Winblad B, Wimo A, Engedal K: 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353–363.
Referenzen
Brodaty H, Corey-Bloom J, Potocnik FC, et al.: Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20: 120–132.
Bullock R, Erkinjuntti T, Lilienfeld S. GAL-INT-6 Study Group: Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004; 17: 29–34.
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–1290.
Koontz J, Baskys A: Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebocontrolled study. Am J Alzheimers Dis Other Demen 2005;20: 295–302.
Raina P, Santaguida P, Ismaila A, et al.: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379–397.
Raskind MA, Peskind ER, Wessel T, et al.: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–2268.
Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–595.
Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–2276.
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445–1449.
Referenzen
Birks JS, Harvey R: Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2003 (3): CD001190.
Birks J, Grimley Evans J, Iakovidou V, et al.: Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2000 (4): CD001191.
Loy C, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 2004 (4): CD001747.
Referenzen
Auchus A, Bissey-Black C: Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591–593.
Birks J, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev. 2000 a (2): CD001191.
Birks J, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev. 2000 b (4): CD001190.
Boustani M, Peterson B, Hanson L, et al.: Screening for dementia in primary care: a summary of the evidence for the U.S. preventive services task force. Ann Int Med 2003; 138: 927–937.
Burns A, Rossor M, Hecker J, et al.: The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–244.
Devanand D, Marder K, Michaels K, et al.: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998; 155: 1512–1520.
Greenberg S, Tennis M, Brown L, et al.: Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–99.
Lyketsos CG, Sheppard JM, Steele CD, et al.: Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease: initial results from the Depression in Alzheimer’s Disease study. Am J Psychiatry 2000; 157: 1686–1689.
Mohs RC, Doody RS, Morris JC, et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–488.
Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002 (3): CD001747.
Petracca G, Teson A, Chemerinski E, et al.: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1996; 8: 270–275.
Qizilbash N, Whitehead A, Higgins J, et al.: Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists Collaboration. JAMA 1998; 280: 1777–1782.
Rosler M, Anand R, Cicin-Sain A, et al.: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–638.
Teri L, Logsdon RG, Peskind E, et al.: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271–1278.
Winblad B, Engedal K, Soininen H, et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–495.
Referenzen
Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–595.
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: Multicentre randomised controlled trial. BMJ 2000; 321: 1445–1449.
Referenzen
Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer’s disease. In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Birks J, Grimley Evans J, et al.: Rivastigmine for Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2005. Oxford: Update Software.
Loy C, Schneider L.: Galantamine for Alzheimer’s disease and mild cognitive impairment. In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Referenzen
Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2001; 16: 852–857.
Referenzen
Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. (Cochrane Review). In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Overshott R, Burns A: Treatment of dementia. J Neurol Neurosurg Psychiatry 2005; 76, Suppl 5: v53–v59.
Referenzen
Clegg A, Bryant J, Nicholson T, et al.: Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: A systematic review. Int J Technol Assess Health Care 2002; 18: 497–507.
Referenzen
Auriacombe S, Pere JJ, Loria-Kanza Y, et al.: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 18: 129–138. Level of evidence: III
Cummings JL: Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11: 131–145. Level of evidence: Ia
Fachbereich Evidenz-basierte Medizin, Ziegler S, Arndt C et al.: Donepezil, Rivastigmin und Galantamin in der Therapie der Demenz vom Alzheimer-Typ. Medizinischer Dienst der Spitzenverbände der Krankenkassen e.V., 2002. Level of evidence: Ia
Farlow M: A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatr 2002; 14, Suppl 1: 93–126. Level of evidence: IV
Finucane TE: Cholinesterase inhibitors for Alzheimer disease. JAMA 2003, 289: 2359 (author reply: 2360-2361). Level of evidence: IV
Hogan DB, Patterson C: Progress in clinical neurosciences: Treatment of Alzheimer’s disease and other dementias — review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 2002; 29: 306–314. Level of evidence: Ia
Poirier J: Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002; (127): 6–19. Level of evidence: IV
Wolfson C, Oremus M, Shukla V, et al.: Donepezil and rivastigmine in the treatment of Alzheimer’s disease: a bestevidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002; 24: 862–886 (discussion: 837). Level of evidence: Ia
Referenzen
Doody RS, Geldmacher DS, Gordon B, et al.: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427–433. (B)
Referenzen
Birks J: Cholinesterase inhibitors for Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620.
Lim WS: Pharmacological treatment of dementia. Singapore Fam Physician 2006; 32: 20–24.
Lovestone S, Gauthier S: Management of dementia. London: Martin Dunitz, 2001.
National Institute for Health and Clinical Excellence: Appraisal consultation document: donepezil, rivastigmine, galantamine (review) and memantine for the treatment of Alzheimer’s disease. London: NICE, 2006 (http://www.nice. org.uk/page.aspx?0=245 098).
Overshott R, Burns A.: Treatment of dementia. J Neurol Neurosurg Psychiatry 2005; 76, Suppl 5: v53–v59.
Winblad B, Kilander L, Eriksson S, et al.: Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebocontrolled study. Lancet. 2006; 367: 1057–1065.
Referenzen
Emre M: Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract Suppl 2002; 127: 64–72.
Gauthier S, Emre M, Farlow MR, et al.: Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Medical Res Opin 2003; 19: 707–714.
Referenzen
McShane R, Areosa Sastre A, Minakaran N: Memantine for dementia (Cochrane Review). In: The Cochrane Library, Issue 2, 2006. Oxford: Update Software.
Peskind ER, Potkin SG, Pomara N, et al.: Memantine treatment in mild to moderate Alzheimer’s disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14: 704–715.
Referenzen
Peskind ER, Potkin SG, Pomara N, et al.: Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14: 704–715.bs]Referenzen
Birks J, Grimley EV, Van Dongen M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (Online) 2002 (4): CD003120.
Van Dongen M, van Rossum E, Kessels A, et al.: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003; 56: 367–376.
Referenzen
Birks J, Grimley Evans J: Ginkgo Biloba for cognitive impairment and dementia (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.
Referenzen
Arzneimittelkommission der deutschen Ärzteschaft: Mitteilungen: «UAW-News” — International — Pseudodemenz/Delir nach Anwendung von Ibuprofen. Dtsch Ärztebl 2004; 101: A-2071/B–1731/C-1663. Level of evidence: K III
Birks J, Grimley EV, van Dongen M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev, 2003 (2): CD003120. Level of evidence: Ia
IQWiG: Ginkgohaltige Präparate bei Alzheimer-Demenz. Vorbericht A05-19B, 2006. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) 2008: 103. Level of evidence: TIa
Kanowski S, Herrmann WM, Stephan K, et al.: Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996; 29: 47–56. Level of evidence: Ib
Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327–1332. Level of evidence: Ib
Van Dongen MC, van Rossum E, Kessels AG et al.: The efficacy of ginkgo for elderly people with dementia and ageassociated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000; 48: 1183–1194. Level of evidence: Ib
Van Dongen M, van Rossum E, Kessels A, et al.: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003; 56: 367–376. Level of evidence: Ib/TIb
Referenzen
Birks J, Grimley Evans J: Ginkgo biloba for cognitive impairment and dementia (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.
Kurz A, van Baelen B: Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on metaanalyses by the Cochrane Collaboration. Dement Geriatr Cogn Disord 2004; 18: 217–226.
Solomon PR, Adams F, Silver A, et al.: Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002; 288: 835–840.
Van Dongen M, Van Rossum E, Kessels AGH, et al.: The efficacy of ginkgo for elderly people with dementia and ageassociated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000; 48: 1183–1194.
Referenzen
Birks J, Grimley EV, Van Dongen M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (Online) 2002 (4): CD003120.
Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327–1332.
Referenzen
Oken B, Storzbach D, Kaye J: The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409–1415.
Referenzen
Birks JS, Harvey R: Donepezil for dementia due to Alzheimer’s disease (Cochrane Review). The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, 2004.
Busse O, Hamann G, Marx P, et al.: Vaskuläre Demenz. In: Diener H, Hacke W (Hrsg): Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Thieme 2003: 201–208.
Doody RS, Stevens JC, Beck C, et al.: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154–1166.
Ernst E, Pittler M: Ginkgo biloba for dementia: A systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 1999; 17: 301–308.
Patterson C, Gauthier S, Bergman H, et al.: The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci 2001; 28, Suppl 1: S3–16.
SIGN. Scottish Intercollegiate Guidelines Network: The management of patients with dementia. A national clinical guideline. Draft 1/January 2003.
Wallesch C, Förstl H, Herholz K, et al.: Alzheimer-Demenz (AD) und Demenz mit Lewy-Körperchen (DLB). In: Diener H, Hacke W (Hrsg): Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Thieme 2003: 96–99.
Referenzen
Boothby LA, Doering PL: Vitamin C and Vitamin E for Alzheimer’s disease. Ann Pharmacother 2005; 39: 2073–2080.
Referenzen
Blacker D: Mild cognitive impairment — no benefit from vitamin E, little from donepezil. N Engl J Med 2005; 352: 2439–2441. Level of evidence: IV
Referenzen
Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.: Meta-analysis: highdosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37–46.
Lim WS, Liscic RM, Xiong CJ, et al.: Letter to the editor: A reply to Meta-Analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 143: 152.
Sano M, Ernesto C, Thomas RG, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Eng J Med 1997; 336: 1216–1222.
Referenzen
Miller ER, 3rd, Pastor-Barriuso R, Dalal D, et al.: Meta-analysis: high-dosage vitamin E supplementation may increase allcause mortality. Ann Int Med 2005; 142: 37–46.
Sano M, Ernesto C, Thomas RG, Klauber MR, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. New Engl J Med 1997; 336: 1216–1222.
Tabet N, Birks J, Grimley Evans J: Vitamin E for Alzheimer’s disease. Cochrane Database Syst Rev (Online) 2000 (4): CD002854.
Referenzen
Sano M, Ernesto C, Thomas RG, Klauber MR, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. New Engl J Med 1997; 336: 1216–1222.
Referenzen
Tabet N, Feldman H: Indomethacin for Alzheimer’s disease (Cochrane review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
Referenzen
Etminan M, Gill S, Samii A: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327: 128. Level of evidence: Ia
Referenzen
Aisen PS, Davis KLM, Berg JDM et al.: A randomised controlled trial of prednisolone in Alzheimer’s disease. Neurology 2000; 54: 588–593.
Aisen PS, Schafer KA, Grundman M, et al.: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomised controlled trial. JAMA 2003; 289: 2819–2826.
Reines SA, Block GA, Morris JC, et al.: Rofecoxib: no effect to Alzheimer’s disease in a 1-year, randomized blinded, controlled study. Neurology 2004; 62: 66–71.
Referenzen
Brooks JO, III, Yesavage JA, Carta A, et al.: Acetyl-L-carnitine slows decline in younger patients with Alzheimer’s disease: A reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 1998; 10: 193–203.
Fioravanti M, Flicker L.: Nicergoline for dementia and other age associated forms of cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Higgins JPT, Flicker L: Lecithin for dementia and cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.
Hudson S, Tabet N: Acetyl-l-carnitine for dementia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Montgomery SA, Thal LJ, Amrein R: Meta-analysis of double blind randomized controlled clinical trials of acetyl-Lcarnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol 2003; 18: 61–71.
Ruether E, Husmann R, Kinzler E, et al.: A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol 2001; 16: 253–263.
Thal LJ, Calvani M, Amato A, et al.: A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology 2000; 55: 805–810.
Referenzen
Aisen PS, Egelko S, Andrews H, et al.: A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11: 246–249. Level of evidence: TIIa
Birks J, Flicker L: Selegiline for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev 2003: 1. Level of evidence: Ia
Clarke, R., Smith, A. D., Jobst, K. A., et al.: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449–1455. Level of evidence: III
Flicker L, Grimley Evans G: Piracetam for dementia or cognitive impairment (Cochrane Review). Cochrane Database Syst Rev 2001: 2. Level of evidence: I
Higgins JP, Flicker L: Lecithin for dementia and cognitive impairment (Cochrane Review). Cochrane Database Syst Rev 2003: 2. Level of evidence: Ia
Homocysteine Lowering Trialists Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894–898. Level of evidence: TIa
Lopez-Arrieta JM, Birks J: Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). Cochrane Database Syst Rev, 2003: 3. Level of evidence: Ia
Malouf R, Areosa Sastre A: Folic acid with or without vitamin B12 for cognition and dementia. (Protocol for a Cochrane Review). In The Cochrane Library 2003. Update Software: Oxford. Level of evidence: IV
Morris MC, Evans DA, Bienias J, et al.: Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 2005; 62: 641–645. Level of evidence: keine Angabe
Pantoni L, Bianchi C, Beneke M, et al.: The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 2000; 175: 116–123. Level of evidence: Ib
Rodriguez-Martin JL, Qizilbash N, Lopez-Arrieta JM: Thiamine for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev 2003: 3. Level of evidence: Ia
Sano M, Ernesto C, Thomas RG, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336: 1216–1222. Level of evidence: Ib
Seshadri S, Beiser A, Selhub J, et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346: 476–483. Level of evidence: III
Shaw DM, Macsweeney DA, Johnson AL, et al.: Folate and amine metabolites in senile dementia: a combined trial and biochemical study. Psychol Med 1971; 1): 166–171. Level of evidence: III
Szatmari S, Whitehouse PJ: Vinpocetine for cognitive impairment and dementia (Cochrane Review). In: The Cochrane Library, 2003. Level of evidence: Ia
Thompson TL, 2nd, Filley CM, Mitchell WD, et al.: Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 1990; 323: 445–448. Level of evidence: Ib
VITAL Trial Collaborative Group: Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med 2003; 254: 67–75. Level of evidence: Ib
Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202. Level of evidence: Ia
Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80 %. BMJ 2003; 326: 1419. Level of evidence: Ia
Wilcock G, Howe I, Coles H, et al.: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 2003; 20: 777–789. Level of evidence: keine Angabe
Referenzen
Birks J, Flicker L: Selegiline for Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
Referenzen
Birks J, Flicker L: Selegiline for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev 2000 (2): CD000442.
Referenzen
Aisen PS, Schafer KA, Grundman M, et al.: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819–2826.
Beard CM, Waring SC, O’Brien PC, et al.: Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998; 73: 951–955.
Bertozzi B, Barbisoni P, Franzoni S, et al.: Association of chronic non-steroidal anti-inflammatory drugs use and cognitive decline in nondemented elderly patients admitted to a geriatric evaluation and rehabilitation unit. Arch Gerontol Geriatr 1996; 23: 71–79.
Etminan M, Gill S, Samii A: Effect of nonsteroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327: 128.
Flicker L, Grimley Evans J: Piracetam for dementia or cognitive impairment (Cochrane Review). The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, 1999.
Fourrier A, Letenneur L, Begaud B, et al.: Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 1996; 49: 1201.
Henderson AS, Jorm AF, Christensen H, et al.: Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 1997; 12: 926–930.
Higgins J, Flicker L: The efficacy of lecithin in the treatment of dementia and cognitive impairment (Cochrane Review). The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2000.
Karplus TM, Saag KG. Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect? Drug Saf 1998; 19: 427–433.
Lopez-Arrieta J, Rodriguez J, Sanz F: Nicotine for Alzheimer’s disease (Cochrane Review). The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, 2003.
Olin J, Schneider L, Novit A, et al.: Hydergine for dementia (Cochrane Review). The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2000.
Prince M, Rabe-Hesketh S, Brennan P: Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology 1998; 50: 374–379.
Qizilbash N, Lopez-Arrieta J, Birks J: Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, 1999.
Rands G, Orrel M, Spector A, et al.: Aspirin for vascular dementia (Cochrane Review). The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2004.
Sano M, Ernesto C, Thomas RG, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336: 1216–1222.
Scharf S, Mander A, Ugoni A, et al.: A double-blind, placebocontrolled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53: 197–201.
Stewart WF, Kawas C, Corrada M, et al.: Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48: 626–632.
Tabet N, Birks J, Grimley Evans J, et al.: Vitamin E Alzheimer’s disease (Cochrane Review). The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, 2003.
Tabet N, Feldman H: Indomethacin for Alzheimer’s disease (Cochrane Review). The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2004 a.
Tabet N, Feldman H: Ibuprofen for Alzheimer’s disease (Cochrane Review). The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2004 b.
Referenzen
Winblad B, Engedal K, Soininen H, et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–495.
Referenzen
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial [comment]. Lancet 2002; 359: 1283–1290.
Malouf R, Birks J: Donepezil for vascular cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: John Wiley & Sons.
Referenzen
Kivipelto M, Helkala E, Laakso MP, et al.: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451. Level of evidence: KIII
Vermeer SE, Prins ND, den Heijer T, et al.: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 48: 1215–1222. Level of evidence: III
Referenzen
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–1290. (A)
Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004 (1): CD004395. (E)
Referenzen
Black S, Roman G, Geldmacher D, et al.: Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week multicenter internationl randomized placebo controlled trial. Stroke 2003; 43: 2323–2332.
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–1290.
Malouf, R, Birks, J: Donepezil for vascular cognitive impairment. Cochrane Library 2005.
Wilkinson D, Doody R, Helme R, et al.: Donepezil in vascular dementia — a randomized placebo controlled study. Neurology 2003; 61: 479–486.
Referenzen
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620.
Winblad B, Kilander L, Eriksson S, et al, for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057–1065.
Referenzen
Auchus AP, Brashear HR, Salloway S, et al.: Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69: 448–458.
Black S, Roman G, Geldmacher D, et al.: Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week multicenter internationl randomized placebo controlled trial. Stroke 2003; 43: 2323–2332.
Craig D, Birks J: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2005 (2): CD004744.
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359): 1283–1290.
Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004 (1): CD004395.
Moretti R, Torre P, Anonello RM, et al.: Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled open 24-month study of 246 patients. Am J Alzheimer Dis Other Dement 2004; 19: 333–339.
Orgogozo JM, Rigaud AS, Stoffler A, et al.: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized placebo-controlled trial (MMM300). Stroke 2002; 33: 1834–1839.
Wilcock G, Möbius HK, Stoeffler A, et al.: A double-blind placebo-controlled multi-centre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297–305.
Wilkinson D, Doody R, Heleme R, et al.: Donepezil in vascular dementia. Neurology 2003; 61: 479–486.
Referenzen
Pantoni L, Rossi R, Inzitari D, et al.: Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci. 2000; 175: 124–134.
Williams P, Rands G, Orrel M, et al.: Aspirin for vascular dementia. Cochrane Database Syst Rev 2000 (4): CD001296.
Referenzen
Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004 (1): CD004395.
Referenzen
Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106. Level of evidence: TIa
The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345–1349. Level of evidence: Ib
Williams PS, Rands G, Orrel M, et al.: Aspirin for vascular dementia (Cochrane Review). Cochrane Database Syst Rev 2003 (2). Level of evidence: Ia
Referenzen
Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351. (A)
Guo Z, Fratiglioni L, Zhu L, et al.: Occurrence and progression of dementianin a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991–996. (C)
Referenzen
Stewart R: Cardiovascular risk factors in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1998; 65: 143–147.
Referenzen
Ariesen M, Algra A, Koudstaal P, et al.: Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. Stroke 2004; 35: 710–714.
De Caterina R, Husted S, Wallentin L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007; 28: 880–913.
Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36: 1588–1593.
Meyer JS, Rogers RL, McClintic K, et al.: Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989; 37: 549–555.
Rands G, Orrel M, Spector A, et al.: Aspirin for vascular dementia. Cochrane Library, 2006, Issue 1.
Referenzen
MRC/CFAS: Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). The Lancet 2001; 357: 169–175.
Referenzen
Areosa Sastre A, Sherriff F: Memantine for dementia (Cochrane Review). In: The Cochrane Library, 2005. Update Software: Oxford. Level of evidence: Ia
Birks J, Grimley Evans J, Iakovidou V et al.: Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2003 a: 2. Level of evidence: Ia
Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer’s disease. Cochrane Database Syst Rev 2003 b: 2. Level of evidence: Ia
Erkinjuntti T, Kurz A, Small GW, et al.: An openlabel extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003; 25: 1765–1782. Level of evidence: Ib
Olin J, Schneider L: Galantamine for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev 2003: 2. Level of evidence: Ia
Pantev M, Ritter R, Görtelmeyer, R: Clinical and behavioral evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Z Gerontopsychol Psychiatr 1993; 6: 103–117. Level of evidence: Ib
Tariot PN, Solomon PR, Morris J, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–2276. Level of evidence: Ib
Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–1599. Level of evidence: Ib
Winblad B, Poritis N: Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–146. Level of evidence: Ib
Referenzen
Emre M: Dementia in Parkinson’s disease: cause and treatment. Curr Opin Neurol 2004; 17: 399–404. (G)
McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–2036. (A)
Wild R, Pettit T, Burns A: Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003 (3): CD003672. (E)
Referenzen
Emre M, Aarsland D, Albanese A, et al.: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–2518.
Leroi I, Brandt J, Reich SG, et al.: Randomised controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19: 1–8.
Maidment I, Fox C, Boustani M: Cholinesterase inhibitors for Parkinsons disease dementia. In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Samuel W, Caliguri M, Galasko D, et al.: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15: 794–802.
Referenzen
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620.
Winblad B, Kilander L, Eriksson S, et al.: Donepezil in patients with severe Alzheimer’s disease: double-blind, parallelgroup, placebo-controlled study. Lancet 2006; 367: 1057–1065.
Referenzen
McGrath A.M, Jackson G: Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 1996; 312: 611–612. Level of evidence: III
Referenzen: in section 7.3.
Baines S, Saxby P, Ehlert K: Reality orientation and reminiscence therapy. A controlled cross-over study of elderly confused people. Br J Psychiatry 1987; 151: 222–231.
Bottino CM, Carvalho IA, Alvarez AM, et al.: Cognitive rehabilitation combined with drug treatment in Alzheimer’s disease patients: a pilot study Clin Rehabil 2005; 19: 861–869.
Breuil V, De Rotrou J, Forette F, et al.: Cognitive stimulation of patients with dementia: preliminary results. Int J Geriatr Psychiatry 1994; 9: 211–217.
Cahn-Weiner D, Malloy PF, Rebok GW, et al.: Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer’s disease patients. Appl Neuropsychol 2003; 10: 215–223.
Chapman SB, Weiner MF, Rackley A, et al.: Effects of cognitive communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004; 47: 1149–1163.
Corbeil RR, Quayhagen MP, Quayhagen M: Intervention effects on dementia caregiving interaction: a stress-adaptation modeling approach. J Aging Health 1999; 11: 79–95.
Davis RN, Massman PJ, Doody RS: Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord 2001; 15: 1–9.
Ferrario E, Cappa G, Molaschi M, et al.: Reality Orientation Therapy in institutionalized elderly patients: preliminary results. Arch Gerontol Geriatr 1991; 12: 139–142.
Heiss WD, Kessler J, Mielke R, et al.: Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer’s disease. A neuropsychological, EEG, and PET investigation. Dementia 1994; 5: 88–98.
Koltai DC, Welsh-Bohmer KA, Smechel DE: Influence of anosognosia on treatment outcome among dementia patients. Neuropsychol Rehabil 2001; 11: 455–475.
Onder G, Zanetti O, Giacobini E, et al.: Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer’s disease: randomised controlled trial. Br J Psychiatry 2005; 187: 450–455.
Quayhagen MP, Quayhagen M, Corbeil RR, et al.: Coping with dementia: evaluation of four nonpharmacologic interventions. Int Psychogeriatr 2000; 12: 249–265.
Spector A, Thorgrimsen L, Woods B, et al.: Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 2003; 183: 248–254.
Wallis GG, Baldwin M, Higginbotham P: Reality orientation therapy — a controlled trial. Br J Med Psychol 1983; 56: 271–277.
Woods RT: Reality orientation and staff attention: a controlled study. Br J Psychiatry 1979; 134: 502–507.
Referenzen
Davis RN, Massman PJ, Doody RS: Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord 2001; 15: 1–9.
Quayhagen MP, Quayhagen M, Corbeil RR, et al.: Coping with dementia: evaluation of four nonpharmacologic interventions. Int Psychogeriatr 2000; 12: 249–265.
Referenzen
Bach D, Bach M, Bohmer F, et al.: Reactivating occupational therapy: a method to improve cognitive performance in geriatric patients. Age Ageing 1995; 24: 222–226.
Beck C, Heacock P, Mercer SO, et al.: Improving dressing behavior in cognitiveley impaired nursing home residents. Nurs Res 1997; 46: 126–132.
Coyne M, Hoskins I: Improving eating behaviors in dementia using behavioral strategies. Clin Nurs Res 1997; 6: 275–291.
Ford M, Fox J, Fitch S, et al.: Light in the darkness. Nurs Times 1987; 83: 26–29.
Hanley I, McGuire R, Boyd W: Reality orientation and dementia: a controlled trial of two approaches. Br J Psychiatry 1981; 138: 10–14.
McEvoy C, Patterson R: Behavioral treatment of deficit skills in dementia patients. Gerontologist 1986; 26: 475–478.
Ouslander J, Schnelle J: Assessment, treatment and management of urinary incontinence in the nursing home. In: Rubenstein L, Wieland D (eds): Improving care in the nursing home: comprehensive review of clinical research. Newbury Park, CA: Sage Publications, 1993: 131–159.
Reichenback V, Kirchman M: Effects of a multi-strategy program upon elderly with organic brain syndrome. In: Taira ED (ed): The mentally impaired elderly. Binghampton, NY: Haworth Press, 1991: 131–151.
Sixsmith A, Stilwell J, Copeland J: Rementia: challenging the limits of dementia care. Int J Geriatr Psychiatry 1993; 8: 993–1000.
Skelly J, Flint AJ: Urinary incontinence associated with dementia. J Am Geriatr Soc 1995; 43: 286–294.
Tappen R: The effect of skill training on functional abilities of nursing home residents with dementia. Res Nurs Health 1994; 17: 159–165.
Zanetti O, Binetti G, Magni E, et al.: Procedural memory stimulation in Alzheimer’s disease: impact of a training programme. Acta Neurol Scand 1997; 95: 152–157.
Referenzen
Dooley NR, Hinojosa J: Improving quality of life for persons with Alzheimer’s disease and their family caregivers: brief occupational therapy intervention. Am Journal Occup Ther 2004; 58: 561–569.
Gitlin, LN, Winter, L, Corcoran, M, et al.: Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH Initiative. Gerontologist 2003; 43: 532–546.
Graff, MJL, Vernooij-Dassen, MJFJ, Hoefnagels, WH, et al.: Occupational therapy at home for older individuals with mild to moderate cognitive impairments and their primary caregivers: a pilot study. Occup Ther J Res 2003; 23: 155–164.
Referenzen
Brodaty H, Green A, Koschera A: Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003; 51: 657–664. (E)
Burgio L, Stevens A, Guy D, et al.: Impact of two psychosocial interventions on white and African American family caregivers of individuals with dementia. Gerontologist 2003; 43: 568–579. (A−)
Chang BL: Cognitive-behavioral intervention for homebound caregivers of persons with dementia. Nurs Res 1999; 48: 173–182. (A−)
Chiverton P, Caine ED: Education to assist spouses in coping with Alzheimer’s disease: a controlled trial. J Am Geriatr Soc 1989; 37: 593–598. (C)
Coon DW, Thompson L, Steffen A, et al.: Anger and depression management: psychoeducational skill training interventions for women caregivers of a relative with dementia. Gerontologist 2003; 43:678–689. (A−)
Gallagher-Thompson D: Direct services and interventions for caregivers: a review and critique of extant programs and a look ahead to the future. In: Cantor MH (ed): Family Caregiving: Agenda for the Future. San Francisco: American Society on Aging, 1994 (pp 101–122). (G)
Gitlin LN, Winter L, Corcoran M, et al.: Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH Initiative. Gerontologist 2003; 43: 532–546. (A−)
Hebert R, Levesque L, Vezina J, et al.: Efficacy of a psychoeducative group program for caregivers of demented persons living at home: a randomized controlled trial. J Gerontol B Psychol Sci Soc Sci 2003; 58:S58–S67. (A−)
King AC, Baumann K, O’Sullivan P, et al.: Effects of moderate-intensity exercise on physiological, behavioral, and emotional responses to family caregiving: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2002; 57: M26–M36. (A−)
Lovett S, Gallagher D: Psychoeducational interventions for family caregivers: preliminary efficacy data. Behav Ther 1988; 19:321–330. (B)
Marriott A, Donaldson C, Tarrier N, et al.: Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer’s disease. Br J Psychiatry 2000; 176: 557–562. (A−)
Mittelman MS, Ferris SH, Steinberg G, et al.: An intervention that delays institutionalization of Alzheimer’s disease patients: treatment of spouse-caregivers. Gerontologist 1993; 33: 730–740. (A−)
Thompson C, Briggs M: Support for carers of people with Alzheimer’s type dementia. Cochrane Database Syst Rev 2000 (2): CD000454. (E)
Referenzen
Beauchamp N, Irvine AB, Seeley J, et al.: Worksite-based internet multimedia programme for family caregivers of persons with dementia. Gerontologist 2005; 45: 793–801.
Brodaty H, Green A, Koschera A: Meta-analysis of psychosocial intervention for caregivers of people with dementia. J Am Geriatr Soc 2003; 51: 657–664.
Czaja SJ, Rubert MP: Telecommunications technology as an aid to family caregivers of persons with dementia. Psychosom Med 2002; 64: 469–476.
Eisdorfer C, Czaja SJ, Loewenstein DA et al.: The effect of a family therapy and technology-based intervention on caregiver depression. Gerontologist 2003; 43: 521–531.
Gitlin LN, Belle SH, Burgio LD, et al.: Effect of multicomponent interventions on caregiver burden and depression: the REACH multisite initiative at 6-month follow-up. Psychol Aging 2003; 18: 361–374.
Mittelman MS, Ferris SH, Shulman E, et al.: A family intervention to delay nursing home placement of patients with Alzheimer’s disease.A randomized controlled trial. JAMA 1996; 276: 1725–1731.
Mittelman MS, Roth DL, Haley WE, et al.: Effects of a caregiver intervention on negative caregiver appraisals of behaviour problems in patients with Alzheimer’s disease: results of a randomised trial. J Gerontolol B Psychol Sci Soc Sci 2004 a; 59B: 27–34.
Mittelman MS, Roth DL, Coon DW, et al.: Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer’s disease. Am J Psychiatry 2004 b; 161: 850–856.
Referenzen
Mittelman MS, Haley WE, Clay OJ, et al.: Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006; 67: 1592–1599.
Referenzen
Small BJ, Mobly JL, Laukka EJ, et al.: Cognitive deficits in preclinical Alzheimer’s disease. Acta Neurol Scand Suppl 2003; 179: 29–33.
Referenzen
Bischkopf J, Busse A, Angermeyer MC: Mild cognitive impairment: A review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand 2002; 106: 403–414. Level of evidence: keine Angaben
Grundman M, Petersen RC, Ferris SH, et al.: Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004; 61: 59–66. Level of evidence: keine Angaben
Petersen RC, Stevens JC, Ganguli M, et al.: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133–1142. Level of evidence: D Ia
Referenzen
Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183–194. (G)
Referenzen
Schmidtke K, Hermeneit S: High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients. Int Psychogeriatr 2008; 20: 96–108.
Referenzen
Nasreddine Z, Phillips N, Bedirian V, et al.: The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699. Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia, Montreal, March 9-11, 2006 (Official conference publication forthcoming).
Referenzen
Biessels GJ, Staekenborg S, Brunner E, et al.: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.
Gustafson D, Rothenberg E, Blennow K, et al.: An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Int Med 2003; 163: 1524–1528.
Kivipelto M, Ngandu T, Fratiglioni L, et al.: Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556–1560.
Ott A, Stolk RP, Van Harskamp F, et al.: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937–1942.
Referenzen
Anttila T, Helkala EL, Viitanen M, et al.: Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 2004; 329: 539. Level of evidence: KIII
Fratiglioni L, Ahlbom A, Viitanen M., et al.: Risk factors for late-onset Alzheimer’s disease: a population-based, casecontrol study. Ann Neurol 1993; 33: 258–266. Level of evidence: III
Hackam DG, Anand SS: Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932–940. Level of evidence: Ia
Honig LS, Tang MX, Albert S, et al.: Stroke and the risk of Alzheimer disease. Arch Neurol 2003; 60: 1707–1712. Level of evidence: keine Angaben
Kivipelto M, Helkala E, Laakso MP, et al.: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451. Level of evidence: KIII
Langa KM, Foster NL, Larson EB: Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004; 292: 2901–2908. Level of evidence: keine Angaben
Ott A, Slooter AJ, Hofman A, et al.: Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet 1998; 351: 1840–1843. Level of evidence: III
Qiu C, Winblad B, Marengoni A, et al.: Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 2006; 166: 1003–1008. Level of evidence: III
Ruitenberg A, Skoog I, Ott A, et al.: Blood Pressure and the Risk of Dementia: Results from the Gothenburg H-70 Study and the Rotterdam Study. Neurology 1999; 52, Suppl 2: A297. Level of evidence: III
Ruitenberg A, Skoog I, Ott A, et al.: Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–39. Level of evidence: III
Saunders PA, Copeland JR, Dewey ME, et al.: Heavy drinking as a risk factor for depression and dementia in elderly men. Findings from the Liverpool longitudinal community study. Br J Psychiatry 1991; 159: 213–216. Level of evidence: III
Seshadri S, Beiser A, Selhub J, et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346: 476–483. Level of evidence: III
Van Oijen M, Witteman JC, Hofman A, et al.: Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005; 36: 2637–2641. Level of evidence: keine Angaben
Referenzen
Stewart R: Cardiovascular risk factors in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1998; 65: 143–147.
Referenzen
Laurin D, Verreault R, Lindsay J, et al.: Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001; 58: 498–504.
Lindsay J, Laurin D, Verreault R, et al.: Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156: 445–453.
Podewils LJ, Guallar E, Kuller LH, et al.: Physical activity, APOE genotype and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005; 161: 639–651.
Referenzen
Caamano-Isorna F, Corral M, Montes-Martinez A, et al.: Education and dementia: a meta-analytic study. Neuroepidemiology 2006; 26: 226–232.
Teri L, Gibbons LE, McCurry SM, et al.: Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003; 290: 2015–2022.
Referenzen
Di Bari M, Pahor M, Franse LV, et al.: Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 2001; 153: 72–78.
Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351.
Forette F, Seux ML, Staessen JA, et al.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046–2052.
Gertz HJ, Wolf H, Arendt T: Vaskuläre Demenz. Nervenarzt 2002; 73: 393–404.
Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.
Pahor M, Somes GW, Franse LV, et al.: Prevention of dementia: Syst-Eur trial. Lancet 1999; 353: 235–237.
Tzourio C, Anderson C, Chapman N, et al.: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–1075.
Referenzen
Andel R, Crowe M, Pedersen NL, et al.: Complexity of work and risk of Alzheimer’s disease: a population-based study of Swedish twins. J Gerontol B Psychol Sci Soc Sci 2005; 60: P251–258. Level of evidence: keine Angaben
Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351. Level of evidence: Ia
Ganguli M, Vander Bilt J, Saxton JA, et al.: Alcohol consumption and cognitive function in late life: a longitudinal community study. Neurology 2005; 65: 1210–1217. Level of evidence: keine Angaben
Larson EB, Wang, Bowen JD, et al.: Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006; 144: 73–81. Level of evidence: keine Angaben
Rovio S, Kareholt I, Helkala EL, et al.: Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol 2005; 4: 705–711. Level of evidence: keine Angaben
Ruitenberg A, van Swieten JC, Witteman JC, et al.: Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002; 359: 281–286. Level of evidence: III
Ruitenberg A, Skoog I, Ott A, et al.: Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–39. Level of evidence: III
Verghese J, Lipton RB, Katz MJ, et al.: Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003; 348: 2508–2516. Level of evidence: III
Referenzen
Shumaker SA, Legault C, Thal L, et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA 2003; 289: 2651–2662. Level of evidence: Ib
Referenzen
Henderson VW, Paganini-Hill A, Miller BL, et al.: Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebocontrolled trial. Neurology 2000; 54: 295–301.
Hogervorst E, Yaffe K, Richards M, et al.: Hormone replacement therapy to maintain cognitive function in women with dementia. In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
Mulnard RA, Cotman CW, Kawas C, et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA. 2000; 283: 1007–1015.
Shumaker SA, Legault C, Rapp SR, et al.: Oestrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomised controlled trial. JAMA 2003; 289: 2651–2662.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2010 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN)
About this chapter
Cite this chapter
Maier, W., Jessen, F., Schneider, F., Deuschl, G., Spottke, A., Reichmann, H. (2010). Leitliniensynopse zur S3-Leitlinie »Demenzen« (November 2009). In: Diagnose- und Behandlungsleitlinie Demenz. Interdisziplinäre S3 Praxisleitlinien, vol 0. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13092-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-13092-2_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13091-5
Online ISBN: 978-3-642-13092-2
eBook Packages: Medicine (German Language)